M
Matthias Eiber
Researcher at University of California, Los Angeles
Publications - 55
Citations - 4045
Matthias Eiber is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Prostate cancer & Biochemical recurrence. The author has an hindex of 24, co-authored 55 publications receiving 2731 citations. Previous affiliations of Matthias Eiber include Technische Universität München & UCLA Medical Center.
Papers
More filters
Journal ArticleDOI
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.
Wolfgang P. Fendler,Wolfgang P. Fendler,Matthias Eiber,Matthias Eiber,Mohsen Beheshti,Jamshed Bomanji,Francesco Ceci,Steven Cho,Frederik L. Giesel,Uwe Haberkorn,Thomas A. Hope,Klaus Kopka,Bernd J. Krause,Felix M. Mottaghy,Heiko Schöder,John Sunderland,Simon Wan,Hans-Juergen Wester,Stefano Fanti,Ken Herrmann +19 more
TL;DR: These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer imaging and are needed for implementation of this modality in science and routine clinical practice.
Journal ArticleDOI
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler,Wolfgang P. Fendler,Jeremie Calais,Matthias Eiber,Matthias Eiber,Robert R. Flavell,Ashley Mishoe,Felix Y. Feng,Hao G. Nguyen,Robert E. Reiter,Matthew Rettig,Shozo Okamoto,Louise Emmett,Helle D Zacho,Harun Ilhan,Axel Wetter,Christoph Rischpler,Heiko Schöder,Irene A. Burger,Jeannine Gartmann,Raven Smith,Eric J. Small,Roger Slavik,Peter R. Carroll,Ken Herrmann,Ken Herrmann,Johannes Czernin,Thomas A. Hope +27 more
TL;DR: Using blinded reads and independent lesion validation, this single-arm prospective trial establishes high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer.
Journal ArticleDOI
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Matthias Eiber,Matthias Eiber,Ken Herrmann,Jeremie Calais,Boris Hadaschik,Frederik L. Giesel,Markus Hartenbach,Thomas A. Hope,Robert E. Reiter,Tobias Maurer,Wolfgang A. Weber,Wolfgang P. Fendler,Wolfgang P. Fendler +12 more
TL;DR: A molecular imaging TNM system (miTNM, version 1.0) is proposed as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI, designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions.
Journal ArticleDOI
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Jeremie Calais,Francesco Ceci,Francesco Ceci,Matthias Eiber,Matthias Eiber,Thomas A. Hope,Michael S Hofman,Christoph Rischpler,Tore Bach-Gansmo,Cristina Nanni,Bital Savir-Baruch,David Elashoff,Tristan Grogan,Magnus Dahlbom,Roger Slavik,Jeannine Gartmann,Kathleen Nguyen,Vincent Lok,Hossein Jadvar,Amar U. Kishan,Matthew Rettig,Robert E. Reiter,Wolfgang P. Fendler,Wolfgang P. Fendler,Johannes Czernin +24 more
TL;DR: Comparing prospectively paired 18F-fluciclovine and PSMA PET-CT scans for localising biochemical recurrence of prostate cancer after radical prostatectomy in patients with low prostate-specific antigen (PSA) concentrations found PSMA should be the PET tracer of choice when PET- CT imaging is considered for subsequent treatment management decisions.
Journal ArticleDOI
68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
Jeremie Calais,Johannes Czernin,Minsong Cao,Amar U. Kishan,John V. Hegde,Narek Shaverdian,Kiri A. Sandler,Fang-I Chu,Christopher R. King,Michael L. Steinberg,Isabel Rauscher,Nina-Sophie Schmidt-Hegemann,Thorsten D. Poeppel,Philipp Hetkamp,Francesco Ceci,Ken Herrmann,Wolfgang P. Fendler,Wolfgang P. Fendler,Matthias Eiber,Matthias Eiber,Nicholas G. Nickols +20 more
TL;DR: A post hoc analysis of an intention-to-treat population of 270 patients who underwent 68Ga-PSMA-11 PET/CT at 4 institutions for BCR after prostatectomy without prior radiotherapy at a PSA level of less than 1 ng/mL implied a major impact on SRT planning.